Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of combining valsartan and amlodipine in the treatment of type 2 diabetes mellitus complicated by hypertension

Hongyan Chen, Wenfang Niu, Chunling Liu, Xiuxiu Yin

Department of Internal Medicine, North China Electric Power University Hospital, Beijing 102206, China;

For correspondence:- Xiuxiu Yin Email: yinxiuxiu85@163.com

Accepted: 02 November 2023 Published: 30 November 2023

Citation: Chen H, Niu W, Liu C, Yin X. Effect of combining valsartan and amlodipine in the treatment of type 2 diabetes mellitus complicated by hypertension. Trop J Pharm Res 2023; 22(11):2342-2347 doi: 10.4314/tjpr.v22i11.14

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy of combining valsartan and amlodipine on patients who were co-morbid with type 2 diabetes mellitus (T2DM) and hypertension.

Methods: The medical records of 110 patients treated in North China Electric Power University Hospital, Beijing, China from July 2018 to October 2022 were retrospectively analyzed. Control group (CG; n = 50) was administered oral amlodipine (5 mg daily for 6 months), while the study group (SG; n = 60) received one tablet of co-formulated valsartan (80 mg)) and amlodipine (5 mg) daily for 6 months. All the patients, in addition to the above drugs, were also placed on insulin and atorvastatin calcium. After a 6-month treatment period, the therapeutic effect and incidence of adverse effects were compared between CG and SG. Blood glucose-related indices (glycosylated hemoglobin (HbA1c), 2 h postprandial blood glucose (2 h PG), and fasting blood glucose (FBG)) and blood pressure indices, viz, (diastolic blood pressure (DBP), systolic blood pressure (SBP)) were compared.

Results: Compared to the pre-treatment values, both groups showed significant decrease in 2 h PG, FBG, HbA1c, SBP and DBP after treatment (p < 0.05), but the 2 h PG, FBG, HbA1c, SBP and DBP in SG were significantly lower in comparison to CG (p < 0.05). The overall response rate (ORR) of CG was significantly lower in comparison to SG (p < 0.05). In SG, there was significant reduction in the incidence of adverse effects compared to CG (p < 0.05).

Conclusion: The combination of valsartan and amlodipine is effective in treating T2DM co-morbid with hypertension, and satisfactorily controls blood glucose level and blood pressure with a relatively high level of safety. Further experiments would be required to ascertain the reliability of these findings.

Keywords: Valsartan, Amlodipine, Type 2 diabetes mellitus, Hypertension